广发证券股份有限公司 关于威海百合生物技术股份有限公司变更募集资金专项账户的 核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为威海 百合生物技术股份有限公司（以下简称"百合股份"或"公司"）首次公开发行 股票并上市持续督导阶段的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所股票上市规则》《上市公司募集资金监管规则》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司自 律监管指引第 11 号——持续督导》等有关规定，对公司变更募集资金专项账户 的事项进行了核查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2022]36 号文核准，本公司于 2022 年 1 月向社会公开发行人民币普通股（A 股）1,600.00 万股，每股发行价为 42.14 元，募集资金总额为人民币 67,424.00 万元，根据有关规定扣除发行费用 7,180.89 万元后，实际募集资金金额为 60,243.11 万元。该募集资金已于 2022 年 1 月到账， 上述资金到账情况业经容诚会计师事务所容诚验字[2022]251Z000 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-042 威海百合生物技术股份有限公司 关于变更募集资金专项账户的公告 二、本次变更募集资金专户的情况 根据公司与中国农业银行股份有限公司威海龙须岛支行（以下简称"农业银 行威海龙须岛支行"）、保荐机构签署的《募集资金三方监管协议》，公司存放 于农业银行威海龙须岛支行（银行账号：15590601048888888）的募集资金，专 项用于"总部生产基地建设项目"的实施。截至 2025 年 6 月 30 日，该募集资金专 户余额为人民币 25,069.89 万元。 为便捷对募集资金专户的日常操作，进一步优化公司募集资金管理结构，提 高资金使用与监管效率，公司决定在青岛银行股份有限公司威海成山支行开立新 的募集资金专项账户，用于承接上述"总部生产基地建设项目"的募集资金存放与 管理。 待该专户内募集资金本息全部划转至新开立的募集资金专户后，公司将及时 办理原在农业银行威海龙须岛支行的募集资金专户（账号：15590601048888888） 的注销手续。原公司与农业银行威海龙须岛支行、保荐机构签署的《募集资金三 方监管协议》随之终止。 公司将与保荐机构和青 ...

（一）募集资金到位情况 根据中国证券监督管理委员会《关于核准威海百合生物技术股份有限公司首 次公开发行股票的批复》（证监许可〔2022〕36 号），公司实际已发行人民币 普通股 1,600 万股，每股发行价格 42.14 元，募集资金总额为人民币 67,424.00 万元，扣除各项发行费用人民币 7,180.89 万元，实际募集资金净额为人民币 60,243.11 万元。容诚会计师事务所（特殊普通合伙）于 2022 年 1 月 20 日出具 了《验资报告》（容诚验字〔2022〕251Z0001 号）。后因证券登记费减免 6.40 万元，实际发行费用较之前减少 6.40 万元，募集资金净额实际为 60,249.51 万元。 公司（含各募投项目实施主体）已按《上市公司募集资金监管规则》等相关 文件的规定，对募集资金采取了专户存储制度，并与保荐机构广发证券股份有限 公司（以下简称"广发证券"）、银行签订了募集资金三方监管协议，用于存放 1 证券代码：603102 证券简称：百合股份 公告编号：2025-041 威海百合生物技术股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-043 威海百合生物技术股份有限公司 关于开展"提质增效重回报"专项行动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 威海百合生物技术股份有限公司（以下简称"公司"）为深入贯彻落实党中 央、国务院关于推动高质量发展、提升上市公司质量的决策部署，积极响应上海 证券交易所《关于开展沪市公司"提质增效重回报"专项行动倡议》，践行"以 投资者为本"的发展理念，进一步提升公司质量与投资价值，增强投资者获得感， 公司特制订"提质增效重回报"专项行动方案，并经公司董事会审议通过。具体 方案如下： 一、聚焦主业发展，提升经营质量 作为专注于营养保健食品研发、生产与销售的高新技术企业，公司产品剂型 丰富，全面覆盖软胶囊、硬胶囊、片剂、粉剂、口服液等主流剂型。公司始终坚 持以研发创新为驱动，紧密跟踪国内外健康消费趋势，持续进行新功能、新原料 产品的开发与技术储备，以满足全球消费者多元化、高品质的健康需求。公司于 2025 年 8 月 25 日完成对 Oranutrition ...

证券代码：603102 证券简称：百合股份 公告编号：2025-040 威海百合生物技术股份有限公司 第四届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 威海百合生物技术股份有限公司（以下简称"公司"）于 2025 年 11 月 21 日 向各位董事发出了召开第四届董事会第十五次会议的通知。2025 年 12 月 1 日， 第四届董事会第十五次会议以通讯及现场投票相结合的表决方式在公司会议室 召开，应出席本次会议的董事 9 人，实际出席本次会议的董事 9 人，公司相关高 级管理人员列席了本次会议。本次会议由董事长刘新力先生召集和主持，会议的 召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规 定。 根据募集资金实际使用以及募投项目实施情况，为保证募投项目建设更符合 公司和股东利益，公司拟将首次公开发行股票募投项目中的"总部生产基地建设 项目"及"总部办公及运营配套建设项目"预计达到可使用状态时间调整为 2026 年 12 月。本次募投项目延期事项不改变募 ...

Group 1 - The core point of the article is that Baihe Co., Ltd. announced the postponement of some fundraising projects during its board meeting held on December 1, 2025 [1] - For the year 2024, Baihe Co., Ltd.'s revenue composition is primarily from nutritional health products, accounting for 99.27%, while other businesses contribute only 0.73% [1] - As of the report, Baihe Co., Ltd. has a market capitalization of 2.7 billion yuan [1]

Group 1 - The food processing sector increased by 0.31% on November 12, with Anjijia Food leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] - Anjijia Food's closing price was 81.22, reflecting a rise of 5.19% with a trading volume of 184,000 shares and a transaction value of 1.509 billion yuan [1] Group 2 - The food processing sector experienced a net outflow of 275 million yuan from institutional investors, while retail investors saw a net inflow of 239 million yuan [2] - The top gainers in the food processing sector included Qianwei Central Kitchen and Xianle Health, with closing prices of 41.48 and 25.23, respectively, reflecting increases of 2.75% and 1.77% [1] - The sector's main stocks showed varied performance, with some experiencing significant declines, such as Gaisijia Food, which fell by 7.31% [2]

Core Viewpoint - The food processing sector experienced a slight increase of 0.37% on November 11, with Gais Food leading the gains, while the overall market indices saw declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4002.76, down 0.39%, and the Shenzhen Component Index closed at 13289.0, down 1.03% [1]. - Gais Food's stock price rose by 4.89% to 15.86, with a trading volume of 270,200 shares and a transaction value of 419 million yuan [1]. Group 2: Individual Stock Performance - Other notable gainers included: - Kangbiter, up 4.65% to 18.92, with a trading volume of 53,400 shares and a transaction value of 99.55 million yuan [1]. - Babi Food, up 4.43% to 32.08, with a trading volume of 167,500 shares and a transaction value of 530 million yuan [1]. - Haixin Food, up 3.12% to 5.29, with a trading volume of 397,300 shares and a transaction value of 208 million yuan [1]. Group 3: Capital Flow - The food processing sector saw a net outflow of 159 million yuan from institutional investors, while retail investors contributed a net inflow of 100 million yuan [2]. - Gais Food had a net inflow of 25.86 million yuan from retail investors, indicating strong interest from individual investors [3].

Core Viewpoint - Baihe Co., Ltd. (603102.SH) reported a decline in institutional ownership in its Q3 2025 financial results, with a total of 695,200 shares held by two institutional investors, representing 1.09% of the total share capital, down 1.51 percentage points from the previous quarter [1] Institutional Ownership - As of October 29, 2025, two institutional investors disclosed their holdings in Baihe Co., Ltd., with a combined ownership of 695,200 shares [1] - The institutional investors include Rongcheng City Yongli Investment Management Co., Ltd. and Nuoan Active Allocation Mixed A [1] - The total institutional ownership percentage decreased by 1.51 percentage points compared to the previous quarter [1] Public Fund Holdings - One new public fund disclosed its holdings this quarter, namely Nuoan Active Allocation Mixed A [1] - A total of 71 public funds were not disclosed in this quarter compared to the previous quarter, including Hai Futong Growth Value Mixed A, Bank of China China Mixed (LOF) A, Xinhua Preferred Consumer Mixed, Nuoan Balanced Mixed A, and Hai Futong Consumer Preferred Mixed A [1]

Core Viewpoint - The announcement provides an overview of the financial performance and operational data of Weihai Bihua Biotechnology Co., Ltd. for the third quarter of 2025, emphasizing the accuracy and completeness of the reported information [1][2][8]. Financial Data Summary - The financial statements for the third quarter of 2025 are unaudited, covering the period from the beginning to the end of the quarter [3][7]. - The company confirms that there are no significant changes in the financial indicators compared to previous periods, and the financial information is guaranteed to be true and complete by the management [2][5]. Operational Performance - The announcement includes key operational data categorized by product type, sales model, and regional distribution, although specific figures are not provided in the text [8]. - The company has reported changes in the number of distributors during the third quarter, indicating adjustments in its distribution network [8]. Management Assurance - The board of directors and senior management affirm their responsibility for the accuracy and completeness of the quarterly report, ensuring that there are no misleading statements or omissions [1][2].